Register
Login:
Share:
Email Facebook Twitter




Sareum Share Chat (SAR)



Share Price: 0.89Bid: 0.88Ask: 0.90Change: 0.00 (0.00%)No Movement on Sareum
Spread: 0.02Spread as %: 2.27%Open: 0.935High: 0.935Low: 0.87Yesterday’s Close: 0.89


Share Discussion for Sareum


Thread View

Please login or register to post a message on Share Chat.

Posts per page:


marineville
Posts: 475
Off Topic
Opinion:No Opinion
Price:0.89
RE: don't normally read express but..
Today 00:40
cheers, thoth. appreciate the welcome coming from you... 'night.
 
Thoth2
Posts: 652
Premium Chat Member
Off Topic
Opinion:No Opinion
Price:0.89
RE: don't normally read express but..
Today 00:36
Marine. Welcome aboard. I recommend immersing yourself in the patents for 48 hours. You won't understand most of it for another week. I didn't. And then the jigsaw . Papers etc etc starts making sense. Doesn't mean it will go up. But I do recommend it. All on the website..
marineville
Posts: 475
Off Topic
Opinion:No Opinion
Price:0.89
don't normally read express but...
Today 00:20
found this while reading about ufos kidnapping one of the kardasians... anyway, too tired to drill down for original info but worth a couple of minutes, unless the EU Clinical Trials Directive isn't relevant here?

http://www.express.co.uk/news/science/673335/Britain-world-leading-scientific-EU-red-tape

brexit's gonna get everywhere, like sand at the beach!

'night, all.
diggit1gold
Posts: 206
Off Topic
Opinion:No Opinion
Price:0.89
trials success
Today 00:10
SAR believe that our selected best in class candidate CCT225737 outstrips the previous generation of CHK1 Inhibitors that were withdrawn by Merck and Pfizer after poor trials results. This is due to our candidates far greater selectivity and oral pharmacokinetics. Also those that are currently being investigated by Lilly ( intravenous administration only ) and Genentech appear to be inferior to ours. What predatory pharma would want to be out of this in the coming weeks and months?.
marineville
Posts: 475
Off Topic
Opinion:No Opinion
Price:0.89
okay... really not a deramp...
Tue 23:58
but maybe a small example of why the sp hasn't quite taken off the way holders would like it to?:

http://www.telegraph.co.uk/news/2016/05/20/breast-cancer-drug-rejected-despite-doubling-in-tumour-destructi/

am sure nowhere near as efficacious as sars but gave some interesting numbers re. price... i'm still holding and looking for a rise, obviously, but a little contrary doesn't really hurt, just adds to context... plus it's damned recent.

glft...
marineville
Posts: 475
Off Topic
Opinion:No Opinion
Price:0.89
RE: AZN
Tue 23:47
really not doing yourself any favours...
diggit1gold
Posts: 206
Off Topic
Opinion:No Opinion
Price:0.89
back
Tue 23:43
to Sar business. What about it guys?.
DonaldStump
Posts: 40
Off Topic
Opinion:No Opinion
Price:0.89
RE: AZN
Tue 23:40
Only to gob$h1tes.
marineville
Posts: 475
Off Topic
Opinion:No Opinion
Price:0.89
RE: AZN
Tue 23:38
brave little suck up...
DonaldStump
Posts: 40
Off Topic
Opinion:No Opinion
Price:0.89
RE: AZN
Tue 23:32
If I want to give you an apt nickname I'll give you one and there's jack all you can do about it sunbeam. Like my previous post, wind that neck in.




Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.